Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation

被引：8
|
作者：
Jentzsch, Madlen [1 ]
Grimm, Juliane [1 ]
Bill, Marius [1 ]
Brauer, Dominic [1 ]
Backhaus, Donata [1 ]
Pointner, Rosmarie [1 ]
Goldmann, Karoline [1 ]
Schulz, Julia [1 ]
Niederwieser, Dietger [1 ]
Platzbecker, Uwe [1 ]
Schwind, Sebastian [1 ]
机构：
[1] Leipzig Univ Hosp, Med Clin & Policlin 1, Hematol & Cellular Therapy, Liebigstr 22,Haus 7, D-04103 Leipzig, Germany
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2021年 / 96卷 / 07期
关键词：
D O I：
10.1002/ajh.26179
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E237 / E239
页数：3
相关论文
共 50 条
  • [1] Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation
    Grimm, Juliane
    Jentzsch, Madlen
    Bill, Marius
    Goldmann, Karoline
    Schulz, Julia
    Niederwieser, Dietger
    Platzbecker, Uwe
    Schwind, Sebastian
    BLOOD ADVANCES, 2020, 4 (16) : 3864 - 3874
  • [2] Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
    Backhaus, Donata
    Jentzsch, Madlen
    Bischof, Lara
    Brauer, Dominic
    Wilhelm, Christina
    Schulz, Julia
    Franke, Georg-Nikolaus
    Poenisch, Wolfram
    Vucinic, Vladan
    Platzbecker, Uwe
    Schwind, Sebastian
    CANCERS, 2021, 13 (22)
  • [3] Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
    Jentzsch, Madlen
    Bischof, Lara
    Ussmann, Jule
    Backhaus, Donata
    Brauer, Dominic
    Metzeler, Klaus H. H.
    Merz, Maximilian
    Vucinic, Vladan
    Franke, Georg-Nikolaus
    Herling, Marco
    Platzbecker, Uwe
    Schwind, Sebastian
    BLOOD CANCER JOURNAL, 2022, 12 (12):
  • [4] Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
    Madlen Jentzsch
    Lara Bischof
    Jule Ussmann
    Donata Backhaus
    Dominic Brauer
    Klaus H. Metzeler
    Maximilian Merz
    Vladan Vucinic
    Georg-Nikolaus Franke
    Marco Herling
    Uwe Platzbecker
    Sebastian Schwind
    Blood Cancer Journal, 12
  • [5] ELN 2017 Risk Classification Predicts Survival of AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
    Hansen, Doris K.
    Nieder, Michael L.
    Thompson, Zachary
    Kim, Jongphil
    Pidala, Joseph A.
    Nishihori, Taiga
    Khimani, Farhad
    Davila, Marco L.
    Mishra, Asmita
    Lazaryan, Aleksandr
    Sallman, David
    Elmariah, Hany
    Sweet, Kendra
    Liu, Hien
    Perez, Lia Elena
    Komrokji, Rami
    Fernandez, Hugo
    Lancet, Jeffrey E.
    Anasetti, Claudio
    Bejanyan, Nelli
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [6] Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation
    Jimenez-Vicente, Carlos
    Charry, Paola
    Suarez-Lledo, Maria
    Merchan Munoz, Beatriz
    Castano-Diez, Sandra
    Isabel Perez-Valencia, Amanda
    Martinez-Roca, Alexandra
    Guijarro, Francesca
    Lopez-Guerra, Monica
    Cortes-Bullich, Albert
    Esteban, Daniel
    Guardia-Torrelles, Ares
    Zugasti, Ines
    Munarriz, Daniel
    Rosinol, Laura
    Urbano-Ispizua, Alvaro
    Fernandez-Aviles, Francesc
    Martinez, Carmen
    Diaz-Beya, Marina
    Rovira, Montserrat
    Queralt Salas, Maria
    Esteve, Jordi
    BLOOD, 2023, 142
  • [7] Real-life validation of prognostic risk stratification according to eln 2017 in patients with AML and allogeneic hematopoietic stem cell transplantation
    Aparicio Perez, C.
    Salas Hernandez, F.
    Gonzalez Teomiro, A. C.
    Paumard Rodriguez, E.
    Garcia Torres, E.
    Rojas Contreras, R.
    Sanchez Garcia, J.
    Serrano Lopez, J.
    Martin Calvo, C.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 122 - 123
  • [8] Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation
    Madlen Jentzsch
    Juliane Grimm
    Marius Bill
    Dominic Brauer
    Donata Backhaus
    Julia Schulz
    Karoline Goldmann
    Dietger Niederwieser
    Uwe Platzbecker
    Sebastian Schwind
    Blood Cancer Journal, 11
  • [9] Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation
    Jentzsch, Madlen
    Grimm, Juliane
    Bill, Marius
    Brauer, Dominic
    Backhaus, Donata
    Schulz, Julia
    Goldmann, Karoline
    Niederwieser, Dietger
    Platzbecker, Uwe
    Schwind, Sebastian
    BLOOD CANCER JOURNAL, 2021, 11 (04)
  • [10] COMPARISON OF THE PROGNOSTIC IMPACT BETWEEN ELN2022 AND ELN2017 RISK CLASSIFICATION IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH AML
    Chen, Weihao
    Zhao, Yeqian
    Shi, Jimin
    Luo, Yi
    Yu, Jian
    Tan, Yamin
    Lai, Xiaoyu
    Liu, Lizhen
    Fu, Huarui
    Ye, Yishan
    Yang, Luxin
    Zhang, Congxiao
    Huang, He
    Zhao, Yanmin
    BONE MARROW TRANSPLANTATION, 2024, 59 : 146 - 147
12345